Carboline derivatives as cGMP phosphodiesterase inhibitors
US6462047B1 · kind B1 · utility
15Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 16, 2001 |
| Grant date | Oct 8, 2002 |
| Priority date | — |
| Expiry date | May 16, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of general structural formula (I) wherein A represents a 5- or 6-membered heteroaryl group containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and use of the compounds, and salts and solvates thereof, as therapeutic agents, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.